Voxilaprevir
- Generic Name
- Voxilaprevir
- Brand Names
- Vosevi
- Drug Type
- Small Molecule
- Chemical Formula
- C40H52F4N6O9S
- CAS Number
- 1535212-07-7
- Unique Ingredient Identifier
- 0570F37359
- Background
Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affectin...
- Indication
Vosevi (Voxilaprevir/Sofosbuvir/Velpatasvir) is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection who have previously been treated with an HCV regimen containing Sofosbuvir without an NS5A inhibitor .
- Associated Conditions
- Previously treated with an HCV regimen containing an NS5A inhibitor Chronic Hepatitis C Genotype 1, Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 2, Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 3, Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 4, Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 5, Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 6, Previously treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor Chronic hepatitis C genotype 1a, Previously treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor Chronic hepatitis C genotype 3
- Associated Therapies
- -
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05717400
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT02402452
- Locations
- 🇩🇪
APEX GmbH, München, Germany
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT02397707
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 101
- Registration Number
- NCT02185794
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.